Paper40909165
Advances of bispecific antibodies using/application in dermatology: a review.
Zhang T and 4 others. Front Allergy, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Advances of bispecific antibodies using/application in dermatology: a review. Papers, record 40909165. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40909165
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References119
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31544849 | Design and Production of Bispecific Antibodies. | Antibodies (Basel) | 2019 | https://conductscience.org/library/papers/31544849 | PubMed |
| 2 | 29471919 | Dupilumab: A review of its use in the treatment of atopic dermatitis. | J Am Acad Dermatol | 2018 | https://conductscience.org/library/papers/29471919 | PubMed |
| 3 | 28887948 | Psoriasis pathogenesis and the development of novel targeted immune therapies. | J Allergy Clin Immunol | 2017 | https://conductscience.org/library/papers/28887948 | PubMed |
| 4 | 26271488 | AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use--improves psoriasis in a human xenograft transplantation model. | Protein Eng Des Sel | 2015 | https://conductscience.org/library/papers/26271488 | PubMed |
| 5 | 37305885 | Psoriasis-like skin rash triggered by a local infection in a patient with eosinophilic granulomatosis with polyangiitis that was well controlled by mepolizumab treatment. | Clin Case Rep | 2023 | https://conductscience.org/library/papers/37305885 | PubMed |
| 6 | 37629154 | Role of Innate Immunity in Allergic Contact Dermatitis: An Update. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37629154 | PubMed |
| 7 | 24828435 | Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19. | MAbs | 2014 | https://conductscience.org/library/papers/24828435 | PubMed |
| 8 | 37481828 | Potential roles of inflammasomes in the pathophysiology of Psoriasis: A comprehensive review. | Mol Immunol | 2023 | https://conductscience.org/library/papers/37481828 | PubMed |
| 9 | 36578492 | Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis. | Front Immunol | 2022 | https://conductscience.org/library/papers/36578492 | PubMed |
| 10 | 27200804 | Relative Efficacy And Safety of Ustekinumab Compared to Anti-TNF-Alfa Therapies in Patients With Active Psoriatic Arthritis. | Value Health | 2014 | https://conductscience.org/library/papers/27200804 | PubMed |
| 11 | 25637431 | Alternative molecular formats and therapeutic applications for bispecific antibodies. | Mol Immunol | 2015 | https://conductscience.org/library/papers/25637431 | PubMed |
| 12 | 28249141 | Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28249141 | PubMed |
| 13 | 38547937 | When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside? | Pharmacol Res | 2024 | https://conductscience.org/library/papers/38547937 | PubMed |
| 14 | 39726595 | A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases. | Front Immunol | 2024 | https://conductscience.org/library/papers/39726595 | PubMed |
| 15 | 31345627 | Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/31345627 | PubMed |
| 16 | 30032191 | Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. | Rheumatology (Oxford) | 2018 | https://conductscience.org/library/papers/30032191 | PubMed |
| 17 | 39596740 | Potential Therapeutic Targets for Combination Antibody Therapy Against Staphylococcus aureus Infections. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39596740 | PubMed |
| 18 | 35401191 | Bispecific Antibodies Progression in Malignant Melanoma. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35401191 | PubMed |
| 19 | 25136781 | Transforming growth factor β--at the centre of systemic sclerosis. | Nat Rev Rheumatol | 2014 | https://conductscience.org/library/papers/25136781 | PubMed |
| 20 | 38650005 | Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. | J Hematol Oncol | 2024 | https://conductscience.org/library/papers/38650005 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42371296 | Atopic Dermatitis: New Targets and Emerging Systemic Therapies. | Am J Clin Dermatol | 2026 | https://conductscience.org/library/papers/42371296 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40909165
GET https://conductscience.org/api/papers/v1/40909165/references?page=2